Submit manuscript...
International Journal of
eISSN: 2470-9980

Vaccines & Vaccination

Editorial Volume 2 Issue 3

Mucosal Versus Systemic Vaccine

Ibrahim MSAW Shnawa

University of Qasim, Iraq

Correspondence: Ibrahim MSAW Shnawa, College of Biotechnology, University of Qasim, Qasim, Babylon, Iraq

Received: June 22, 2016 | Published: June 23, 2016

Citation: Shnawa IM (2016) Mucosal Versus Systemic Vaccine. Int J Vaccines Vaccin 2(3): 00033. DOI: 10.15406/ijvv.2016.02.00033

Download PDF

Editorial

Immune responses to immunogens (vaccine) time curve in general is graphically represented and partitioned into primary and secondary for humoral immune responses. The primary subdivided in to lag, peak and decline. While secondary needs short lag followed by peak due to memory cell functions and affinity maturation. The cellular basis for these responses starts by the uptake of antigen(s), antigen processing, antigen assembly on APC surface in combination with MHC molecules, immune recognition events which covers naïve helper cell activation, conversion to TH1,TH2 which in turn activate resting B or T to into effect or B, effect or T, memory B or memory T cells.1 The immune features of mucosal and systemic responses vaccines were depicted in Table 1. The overall events may take around one week for mucosal and around two weeks for the systemic responses.2‒4 These features make mucosal vaccination rather better than systemic vaccination for the benefits of the patients, under risk subjects and contacts,2,3 providing taking in consideration some limitations like, the infection nature, epitope potentials of, immunogenicity, replica-bility and possibility of tolerance induction as in oral mucosa.5

Features

Mucosal Vaccination

Systemic Vaccination

Link

Linked to systemic in some ways

Linked to mucosal in some ways

Application

Direct to the mucosal site

Mostly indirect to the site

Fate

Remains local

Distributed and targeted

Loss in hid , compartment

Relatively no apparent loss

Possible loss

Immune conversion rate in term of time from baseline to vaccinated titer

It takes relatively one week

It take relatively two weeks

Rating antibody - titers in vaccinated

M:S = 1 : 1 -20

S : M = 1 - 20 : 1

Class of antibody

SIgA, leastly IgG

IgM, IgG, IgA

Antibody Structure

Contains secretary ,piece,2ME resistant

No secretory piece,2ME sensitive

Antibody transudation

Systemic transudation in low titers to mucosal compartments

No such transudation from mucosal to systemic.

Immune Protection

Seems to be more protective than systemic, though it depends on the nature of the vaccine

Seems to be less protective than mucosal, though it depends on the nature of the vaccine

Replica-bility

Replicable vaccine more protective than non.

As in mucosal

Table 1 Features of mucosal and systemic vaccination program2‒6

Acknowledgments

None.

Conflicts of interest

Author declares there are no conflicts of interest.

Funding

None.

References

  1. Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. (8th edn), Elsevier, Saunders, Philadelphia. 2015. p.1‒12.
  2. Kiyono H, Orga PL, McGhee JR. Mucosal Vaccines. Academic Press, London. 1996. p.3‒33.
  3. Kaufmann SHE. Novel Vaccine Strategies. Wiley-VCH, Germany. 2004. p.19‒39.
  4. Shnawa IMS. Mucosal Immunology. Lap lambert Academic Publications, Germany. 2013.
  5. Shnawa IMS. Oral Immune tolerance versus oral immune silencing; Minireview. Am J Bimed Life Sci. 2015;3(4‒1):7‒9.
  6. Shnawa IMS. Lapin Systemic versus mucosal humoral immune responses as well as Cellular immune responses following intravenous administration of C. fetus heat killed bacterin: A correlative approach. ALQ J Vet Med Sci. 2006;5(1):47‒51.
Creative Commons Attribution License

©2016 Shnawa. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.